Architecture
Commercialization architecture
Building rare-disease and specialty-care businesses from market entry to launch execution.
ZBRA Pharma Consulting
Explore your Korea/APAC rare-disease market-entry readiness - before building a full local organization.
For global biotech and specialty-care companies considering Korea or APAC entry, ZBRA helps clarify market access, evidence, stakeholder, partner, and lean commercialization requirements before major investment.
Answer ~20 questions
Executive-recognizable prompts across access, evidence, stakeholders, partner model, launch, and patient pathway.
See your readiness profile
Radar, bars, risk heatmap, entry timeline, and a recommended operating-model archetype.
Discuss with ZBRA
Use the profile to focus a strategic discussion on the gaps that matter before local build-out.
Division of value
The tool creates structure. Chad brings judgment.
ZBRA (Chad)
Expert judgment and commercialization architecture across market access logic, partner model, stakeholder orchestration, and evidence planning.
This diagnostic
A structured front door: visual readiness profile, lead capture, meeting conversion, and a clear bridge into expert review.
Access
Korea/APAC market-access judgment
Pricing, reimbursement, RSA, RWE, stakeholder alignment, and launch sequencing.
Lean execution
Virtual-subsidiary thinking
Fractional leadership and partner orchestration for companies not ready to build a full local team.